KVK Tech, Inc. Announces 1-2-3 Savings Program for Lomaira™ (phentermine hydrochloride USP) 8 mg Tablets, CIV Cost Savings for Lomaira Patients NEWTOWN, PA., May 2, 2018 /PRNewswire/ — KVK Tech, Inc. (KVK), a leading American developer, manufacturer, and marketer of FDA-approved pharmaceuticals today announced the LOMAIRA 1-2-3 program. The 1-2-3 program allows patients to start… Read more »

Recent Comments